Trial Profile

A Double-Blind, Placebo-Controlled 16-Week Study of the Cognitive Effects of Oral p38 Alpha Kinase Inhibitor Neflamapimod in Dementia With Lewy Bodies (DLB)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 16 Oct 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Oct 2024 According to an abstract presented at the Alzheimer's Association International Conference 2024, ''A phase 2b clinical study, designed to confirm phase 2a and demonstrate proof-of-concept of neflamapimod as a treatment for DLB, is ongoing and is anticipated to read out results in the second half of 2024.
26 Sep 2024 According to a CervoMed media release, Plasma biomarker data from this study will be presented as oral presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD) taking place October 29 - November 1, 2024, in Madrid, Spain.
29 Jul 2024 Results presented in a CervoMed Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com